Press Room


    Press Release - April 16, 2007

    Journal of Clinical Immunology: Sertoli Cells Could Replace Immunosuppressive Drugs in Humans

    Sernova Corp. (TSX-V: SVA) is pleased to announce the peer reviewed, scientific publication of a Sertoli cell study on humans, co-authored by Dr. David White, Sernova's principal researcher and Novartis/Stiller Chair of Xenotransplantation at the University of Western Ontario. The study is published in the March 2007 issue of The Journal of Clinical Immunology.

    The study reviewed a 6-year follow-up of the immune responses in human diabetic patients who received transplants of porcine Sertoli cells and insulin producing islets without immunosuppressive drugs. The results confirmed that the Sertoli cells reduce the immune responses and allow the survival of the transplanted islets. This is the first human study demonstrating the potential of porcine Sertoli cells for replacing anti-rejection drugs in transplants. Sernova Corp owns the exclusive rights to over 20 patents related to the therapeutic use of Sertoli cells, which are a key component of Sertolin, the Company's experimental diabetes treatment.

    David White noted that "Sernova's experimental animal models have confirmed what we see in the clinical results: Sertoli cells provide a means to co-transplant other cell types and provide immune protection without the need for immunosuppressive drugs. Our research has found a way to improve the immunoprotective properties of the Sertoli cells, but this study's data is still useful to us because it demonstrates clinical benefit in humans and that should enhance our efforts to prove the technology and gain regulatory approval for its use in humans. "

    Justin Leushner, President of Sernova stated "It is encouraging to see evidence that the Sertoli cells do indeed provide immune protection in humans. Having a cell type that is immunoprivileged and can therefore be implanted without the need for anti-rejection drugs provides us with a pipe-line for a host of other therapeutic applications. Our current focus is the co- transplantation of insulin producing cells with our Sertoli cell technology for treating insulin dependent diabetes. However this does not preclude us from using Sertoli cells with other cell types or even using Sertoli cells as a vehicle for gene therapy."

    About Sernova Sernova Corp. is a Canadian based, health sciences company focused on commercializing medical technologies and currently working to cure insulin dependent diabetes using its patented Sertolin technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. Over $100 billion per year is spent in the US on treating diabetes and its complications, and worldwide expenditures on insulin is estimated to be $25 billion annually.

    This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

    ON BEHALF OF THE BOARD "Justin Leushner" Justin Leushner, President

    For further information contact: TEL: (888) 318-7062 FAX: (250) 868-8493

    Phil Morehouse Sernova Corp.



    Press Releases from:

    2018 2017 2016 2015 2014 2013 2012

    2011 2010 2009 2008 2007 2006 2005

    2004 2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs


    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance


    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario


    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Author: James Finch

    Presentation and Video

    May 03, 2018

    Corporate Presentation

    April 2018

    March 29, 2018

    2018 Financial Report - 1st Quarter

    March 29, 2018

    2018 Management Discussion & Analysis (MD&A) - 1st Quarter

    December 11, 2017

    Clearance by FDA of Sernova's US IND

    Conference call audio recording

    September 11, 2017

    Sernova Fact Sheet

    Subscribe to Sernova News